KRASCENDO 2 / CO45042

Study Number: KRASCENDO 2 / CO45042

Please Note:

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).

Available Sites

• Missouri Baptist Medical Center
• Parkland Health Center - Farmington

Contact Person(s)

• Meredith Putney 314-996-5868

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.